Vertex Pharmaceuticals Incorporated
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2010-01-05
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT00966602
Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2010-01-07
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 30
- Registration Number
- NCT00958152
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2015-09-11
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 140
- Registration Number
- NCT00953706
- Locations
- 🇺🇸
Maine Medical Center, Portland, Maine, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors
- Conditions
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Registration Number
- NCT00923728
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Virology Follow up Study in Subjects Previously Treated With Telaprevir
- First Posted Date
- 2009-06-09
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 408
- Registration Number
- NCT00916474
- Locations
- 🇺🇸
Maryland, Baltimore, Maryland, United States
🇺🇸South Carolina, Columbia, South Carolina, United States
🇺🇸Florida, Miami, Florida, United States
Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection
- Conditions
- Interventions
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2014-03-10
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 49
- Registration Number
- NCT00911963
- Locations
- 🇺🇸
Alamo Medical Research, San Antonio, Texas, United States
🇨🇦Downtown ID Clinic/University of British Columbia, Vancouver, British Columbia, Canada
🇨🇦Ottawa Hospital, Ottawa, Ontario, Canada
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2012-08-21
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 52
- Registration Number
- NCT00909727
- Locations
- 🇺🇸
The Children's Mercy Hospital, Kansas City, Missouri, United States
🇺🇸Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸Riley Hospital for Children, Indianapolis, Indiana, United States
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 167
- Registration Number
- NCT00909532
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇦🇺Royal Children's Hospital Brisbane, Herston, Queensland, Australia
Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2015-08-28
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 93
- Registration Number
- NCT00865904
Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects
- Conditions
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2009-02-19
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 72
- Registration Number
- NCT00789126